In this first monthly update of our living review ([@r1-0887]), we searched MEDLINE (Ovid) weekly from 4 May to 8 June 2020 using the same search strategy described in the original review, and we also identified additional citations from consultation with content experts. Searches yielded 138 results; independent dual review of these records identified 4 new studies (see [Supplement Tables 1 and 2](#s1-L200887){ref-type="supplementary-material"}) and 2 in-progress trials for inclusion.

###### 

Click here for additional data file.

New Evidence
============

One new retrospective cohort study examined the association between angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) use and the likelihood of testing positive for COVID-19 ([@r2-0887]). This study included all patients who had testing in 1 health system in 2 different states; patients with symptoms were prioritized for testing at the time so most patients were likely to have been symptomatic. As in the previous review that identified 3 similar studies, neither ACEI nor ARB use was associated with likelihood of testing positive for COVID-19.

This study also examined the association between ACEI or ARB use and COVID-19 illness severity. It found use of these medications was associated with a moderate increase in hospitalization and intensive care unit admission risk but not risk for mechanical ventilation ([@r2-0887]). We found an additional 3 new studies evaluating the association between ACEI or ARB use and COVID-19 illness severity. Two were small single-center retrospective cohort studies from China that found that ACEI or ARB use was not associated with an increased risk for death or severe COVID-19 illness ([@r3-0887], [@r4-0887]). A nationwide retrospective cohort study from Korea similarly found that these medications were not associated with severity of illness after adjustment for demographic characteristics, comorbid conditions, and hospital type ([@r5-0887]).

The 2 studies from China included small, highly select patient populations and did not describe in detail how ACEI or ARB exposure was determined. The 2 larger studies were generally methodologically sound, although 1 study cautioned that the number of patients treated with ACEI or ARBs who had the outcomes of intensive care unit admission or mechanical ventilation was small ([@r2-0887]). (See [Supplement Table 3](#s1-L200887){ref-type="supplementary-material"} for methodological strengths and weaknesses of the studies.)

Of note, 1 international study that examined the association between ACEI or ARBs and severity of COVID-19 illness has since been retracted by the journal in which it was published ([@r6-0887]). We will no longer consider results of this study in determining overall effects or certainty of evidence.

Overall, the addition of the new studies and the retraction of 1 prior study does not change the findings or certainty of evidence ratings we reported in the original review.

In-Progress Trials
==================

We identified 2 randomized controlled trials, currently in progress, that will compare the effects of continuing or withdrawing ACEI or ARB treatment on clinical outcomes in patients hospitalized with COVID-19. One is a U.S. study ([@r7-0887]) and the other is a Brazilian study ([@r8-0887]), and both are expected to be completed by the end of 2020.

This article was published at Annals.org on 25 June 2020.
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